Taurine attenuates CD3/interleukin-2-induced T cell apoptosis in an in vitro model of activation-induced cell death (AICD)

Clinical and Experimental Immunology

Volumn 139, Issue 2, 2005, Pages 279-286

  Maher, S G ^a   Condron, C E M ^a   Bouchier Hayes, D J ^a   Toomey, D M ^a,b  

^a BEAUMONT HOSPITAL   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

FasL; Interleukin 2; Nuclear factor kappa B; T cell; Taurine

Indexed keywords

CD3 ANTIGEN; FAS LIGAND; INTERLEUKIN 2; TAURINE;

ACTIVATION INDUCED CELL DEATH; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CELL DEATH; CELL TYPE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LEUKEMIA CELL LINE; LYMPHOCYTOPENIA; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; APOPTOSIS; FAS LIGAND PROTEIN; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; JURKAT CELLS; MEMBRANE GLYCOPROTEINS; NEOPLASMS; NF-KAPPA B; T-LYMPHOCYTES; TAURINE;

EID: 13544259553     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2005.02694.x     Document Type: Article

References (35)

1. Waldmann TA. Immunotherapy: past, present and future. Nat Med 2003; 9:269-77.
2. Lenardo MJ. Fas and the art of lymphocyte maintenance. J Exp Med 1996; 183:721-4.
3. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4 mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumour immunotherapy. Ann Rev Immunol 2001; 19:565-94.
4. Nagata S. Apoptosis by death factor. Cell 1997; 88:355-65.
5. Maher S, Toomey D, Condron C, Bouchier-Hayes D. Activation-induced cell death. The controversial role of Fas and Fas ligand in immune privilege and tumour counterattack. Immunol Cell Biol 2002; 80:131-7.
6. Lenardo MJ. Interleukin-2 programs mouse αβ T lymphocytes for apoptosis. Nature 1991; 353:858-61.
7. Lotze MT, Matory YL, Ettinghausen SE et al. In vivo administration of purified human interleukin 2, II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 1985; 135:2865-75.
8. Whitehead RP, Freidman KD, Clark DA, Pagini K, Rapp L. Phase I trial of simultaneous administration of interleukin 2 and interleukin 4 subcutaneously. Clin Cancer Res 1995; 1:1145-52.
9. Rosenberg SA, Lotze MT, Yang JC et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210:474-85.
10. Finnegan NM, Redmond HP, Bouchier-Hayes DJ. Taurine attenuates recombinant interleukin-2-activated, lymphocyte-mediated endothelial cell injury. Cancer 1998; 82:186-99.
11. Itoh K, Balch CM, Murray JL et al. Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies. In Vivo 1991; 5:647-54.
12. Son YI, Dallal RM, Lotze MT. Combined treatment with interleukin-18 and low-dose interleukin-2 induced regression of a murine sarcoma and memory response. J Immunother 2003; 26:234-40.
13. Finnegan N, Toomey D, Condron C, Redmond HP, Da Costa M, Bouchier-Hayes D. Potentiation of the therapeutic index of IL-2 immunotherapy by combination with taurine in a syngeneic murine tumour model. Irish J Med Sci 2002; 170:223-7.
14. Stapleton PP, O'Flaherty L, Redmond HP, Bouchier-Hayes DJ. Host defence - a role for the amino acid taurine. JPEN Parenteral and Enteral Nutrition 1998; 22:42-8.
15. Timbrell JA, Seabra V, Waterfield CJ. The in vivo and in vitro protective properties of taurine. Gen Pharmacol 1995; 26:453-62.
16. Watson RW, Redmond HP, Wang JH, Bouchier-Hayes DJ. Mechanisms involved in sodium arsenite-induced apoptosis of human neutrophils. J Leukoc Biol 1996; 60:625-32.
17. Redmond HP, Wang JH, Bouchier-Hayes D. Taurine attenuates nitric oxide- and reactive oxygen intermediate-dependent hepatocyte injury. Arch Surg 1996; 131:1280-7.
18. Wang JH, Redmond HP, Watson RW, Condron C, Bouchier-Hayes DJ. The beneficial effect of taurine on the prevention of human endothelial cell death. Shock 1996; 6:331-8.
19. Lang F, Madlung J, Siemen D, Ellory C, Lepple-Wienhues A, Gulbins E. The involvement of caspases in the CD95 (Fas/Apo-1)-but not swelling-induced cellular taurine release from Jurkat T-lymphocytes. Pflugers Arch 2000; 440:93-9.
20. Wesselborg S, Jannsen O, Kabelitz D. Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. J Immunol 1993; 150:4338.
21. Fanning NF, Porter J, Shorten GD et al. Inhibition of neutrophil apoptosis after elective surgery. Surgery 1999; 126:527-34.
22. + T lymphocyte clones. J Immunol 1997; 158:5612-8.
23. Klas C, Debatin KM, Jonker RR, Krammer PH. Activation interferes with the APO-1 pathway in mature human T cells. Int Immunol 1993; 5:625-30.
24. Cheng J, Zhou T, Liu C et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263:1759-62.
25. Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J 1995; 14:1129-35.
26. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nat Med 1998; 4:31-6.
27. Martinez-Lorenzo MJ, Anel A, Gamen S et al. Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles. J Immunol 1995; 163:1274-81.
28. Kasibhatla S, Genestier L, Green DR. Regulation of Fas-ligand expression during activation-induced cell death in T lymphocytes via nuclear factor κB. J Biol Chem 1999; 274:987-92.
29. Mercurio F, Manning AM. NFκB as a primary regulator of the stress response. Oncogene 1999; 18:6163-71.
30. Hsu SC, Gavrilin MA, Lee HH, Wu CC, Han SH, Lai MZ. NF-kappa B-dependent Fas ligand expression. Eur J Immunol 1999; 29:2948-56.
31. Gurujeyalakshmi G, Wang Y, Giri SN. Suppression of bleomycin-induced nitric oxide production in mice by taurine and niacin. Nitric Oxide 2000; 4:399-411.
32. Sovak MA, Bellas RE, Kim DW et al. Aberrant nuclear factor-kappa B/Rel expression and the pathogenesis of breast cancer. J Clin Invest 1997; 100:2952-60.
33. Bours V, Dejardin E, Goujon-Latawe F, Merville MP, Castronovo V. The NF-kappa B transcription factor and cancer: high expression of NF-kappa B- and I-kappa B-related proteins in tumour cell lines. Biochem Pharmacol 1994; 47:145-9.
34. Hammarskjold ML, Simurda MC. Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type-1 long terminal repeat through induction of NF-kappa B activity. J Virol 1992; 66:6496-501.
35. Andela VB, Gordon AH, Zotalis G et al. NFkappaB: a pivotal transcription factor in prostate cancer metastasis to bone. Clin Orthop 2003; 415:S75-85.